These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 19453758

  • 1. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z.
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [Abstract] [Full Text] [Related]

  • 2. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
    Moayedi B, Gharagozloo M, Esmaeil N, Maracy MR, Hoorfar H, Jalaeikar M.
    Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
    [Abstract] [Full Text] [Related]

  • 3. Immunomodulatory effects of silymarin in patients with β-thalassemia major.
    Gharagozloo M, Karimi M, Amirghofran Z.
    Int Immunopharmacol; 2013 Jun; 16(2):243-7. PubMed ID: 23624215
    [Abstract] [Full Text] [Related]

  • 4. Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients.
    Alidoost F, Gharagozloo M, Bagherpour B, Jafarian A, Sajjadi SE, Hourfar H, Moayedi B.
    Int Immunopharmacol; 2006 Aug; 6(8):1305-10. PubMed ID: 16782543
    [Abstract] [Full Text] [Related]

  • 5. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, Pagano L, Prossomariti L.
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [Abstract] [Full Text] [Related]

  • 6. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T, Ferro G, Frontini V, Percolla S.
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [Abstract] [Full Text] [Related]

  • 7. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maiello A, Lucarelli G.
    Haematologica; 1995 Jan; 80(4):300-4. PubMed ID: 7590497
    [Abstract] [Full Text] [Related]

  • 8. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 Jan; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

  • 9. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 10. Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience.
    Songdej D, Sirachainan N, Wongwerawattanakoon P, Sasanakul W, Kadegasem P, Sungkarat W, Chuansumrit A.
    Acta Haematol; 2015 Feb; 133(2):226-36. PubMed ID: 25376266
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
    Arandi N, Haghpanah S, Safaei S, Zahedi Z, Ashrafi A, Eatemadfar P, Zarei T, Radwan AH, Taher AT, Karimi M.
    Transfus Med; 2015 Feb; 25(1):8-12. PubMed ID: 25801075
    [Abstract] [Full Text] [Related]

  • 12. Spermatogenesis in young adult patients with beta-thalassaemia major long-term treated with desferrioxamine.
    De Sanctis V, Borsari G, Brachi S, Govoni M, Carandina G.
    Georgian Med News; 2008 Mar; (156):74-7. PubMed ID: 18403814
    [Abstract] [Full Text] [Related]

  • 13. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
    Shamsian BS, Aminasnafi A, Moghadassian H, Gachkar L, Arzanian MT, Alavi S, Esfehani H, Garallahi F, Amini R.
    Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
    [Abstract] [Full Text] [Related]

  • 14. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
    Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, Zimmermann A, Manz C.
    Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
    Zareifar S, Jabbari A, Cohan N, Haghpanah S.
    Arch Iran Med; 2009 Sep; 12(5):488-91. PubMed ID: 19722772
    [Abstract] [Full Text] [Related]

  • 16. Chelation therapy in beta-thalassemia major: a one-year double blind study of 2,3-dihydroxybenzoic acid.
    Peterson CM, Graziano JH, Grady RW, Jones RL, Markenson A, Lavi U, Canale V, Gray GF, Cerami A, Miller DR.
    Exp Hematol; 1979 Feb; 7(2):74-80. PubMed ID: 371974
    [Abstract] [Full Text] [Related]

  • 17. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004 Feb; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.
    Hagag AA, Elfaragy MS, Elrifaey SM, Abd El-Lateef AE.
    Infect Disord Drug Targets; 2015 Feb; 15(3):189-95. PubMed ID: 26239735
    [Abstract] [Full Text] [Related]

  • 19. Iron studies in infants born to an iron overloaded mother with beta-thalassemia major: possible effects of maternal desferrioxamine therapy.
    Pearson HA.
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):160-2. PubMed ID: 17356394
    [Abstract] [Full Text] [Related]

  • 20. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases].
    Fehér J, Deák G, Müzes G, Láng I, Niederland V, Nékám K, Kárteszi M.
    Orv Hetil; 1989 Dec 17; 130(51):2723-7. PubMed ID: 2574842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.